Pharmacotherapy of Myopic Choroidal Neovascularization

Title:Pharmacotherapy of Myopic Choroidal Neovascularization

Volume: 24 Issue: 41

Author(s): Hacer Isildak, Stephen G. Schwartz*Harry W. Flynn

Affiliation:

• Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL,United States

Keywords: Myopic choroidal neovascularization, pharmacotherapy, photodynamic therapy, verteporfin, anti-VEGF, bevacizumab, ranibizumab, aflibercept, pegaptanib.

Abstract: Background: Myopic choroidal neovascularization (CNV) is a common cause of central visual loss in patients with high myopia, and the most common form of CNV in younger individuals. Pharmacologic therapy is the current mainstay of treatment of these patients.

Methods: Review of pharmacological treatment options for myopic CNV, which primarily involves intravitreal administration of anti-vascular endothelial growth factor (anti-VEGF) agents.

Results: At this time, anti-VEGF therapy agents are the first-line therapy in these patients. Comparative trials have not identified any major differences in treatment outcomes between aflibercept, bevacizumab, and ranibizumab. Only ranibizumab is approved for this indication in the US. Best visual outcomes are associated with younger age, smaller lesion size, and absence of chorioretinal atrophy.

Conclusion: Anti-VEGF therapy is generally very effective in the treatment of myopic CNV.

Cite this article as:

Isildak Hacer, Schwartz G. Stephen *, Flynn W. Harry , Pharmacotherapy of Myopic Choroidal Neovascularization, Current Pharmaceutical Design 2018; 24 (41) . https://dx.doi.org/10.2174/1381612825666190124102641